Humana (Humana Inc.) is back in focus after its latest earnings update, which combined higher revenue with slightly weaker net income and a downward revision to its full-year GAAP diluted earnings per share (EPS) outlook. The shift has prompted investors to reassess whether the recent share price strength is justified.

Stock futures are slipping while oil prices climb as markets brace for President Trump’s high-stakes Tuesday night deadline for Iran to reopen the Strait of Hormuz. Despite the geopolitical tension, a boost in health insurance stocks and news of a potential $2 trillion SpaceX IPO are helping to offset broader losses.

Danish drugmaker Novo Nordisk has agreed on a Medicare pricing deal for semaglutide, the active ingredient in its blockbuster weight-loss and diabetes drugs Ozempic and Wegovy, easing investor concerns over steep U.S. pricing cuts.

UnitedHealth Group issued a grim 2025 earnings forecast on Tuesday, falling far short of Wall Street’s expectations as high medical costs continue to pressure its insurance business.

Humana (NYSE:HUM) has reported third-quarter profit and revenue that topped estimates, in a positive development for the health insurance group following recent setbacks, News.Az reports citing Investing.